| Document |
Document Title |
|
WO/2013/036671A1 |
The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein L and Ring A are as defined and described herein, compositions thereof, and methods of using the same.
|
|
WO/2013/033901A1 |
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, ...
|
|
WO/2013/033900A1 |
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, ...
|
|
WO/2013/032278A1 |
The present invention relates to a novel compound and an organic electroluminescent device containing the same. Since the compounds according to the present invention have high efficiency in transporting electrons, crystallization could ...
|
|
WO/2013/032297A1 |
The present invention relates to novel organic electroluminescence compounds and an organic electroluminescence device containing the same. The compounds according to the present invention have high luminous efficiency and long operation...
|
|
WO/2013/032960A2 |
Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin D receptor target gene, inhibiting interactions between the vitamin D receptor and at least one vitamin D receptor coactiv...
|
|
WO/2013/029479A1 |
Disclosed in the present invention is a mycophenolic acid derivative shown by the following general formula (V) and the pharmaceutically acceptable salts thereof, wherein L1 is -O-R2, -QCOOR2 or -QCONR2R3, Q is C1~C10. Alkylidene or C1~C...
|
|
WO/2013/026724A1 |
The present invention relates to compounds of formula (IA) wherein QA is QA1 or QA2 P is P1, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, Z, R1, R2, R3 and R4 are as defined in claim 1; or a ...
|
|
WO/2013/027000A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them an...
|
|
WO/2013/027001A1 |
The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6,...
|
|
WO/2013/028045A2 |
The present invention relates to an epoxy compound having an alkoxysilyl group, a method for preparing same, a composition and cured material comprising same, and usage thereof. A composite comprising the epoxy compound exhibits superior...
|
|
WO/2013/026726A1 |
The present invention provides compounds of formula I wherein Q is Q1 or Q2; A1, A2, A3 and A4 are independently of each other C-H, C-R7, or nitrogen; R1 is C1-C8haloalkyl; R2 is aryl or aryl substituted by one to five R11, or heteroaryl...
|
|
WO/2013/025074A2 |
The present invention relates to an anticancer or antioxidant composition containing, as an active ingredient, a Quamoclit pennata extract or a novel compound derived from Quamoclit pennata. The composition according to the present inven...
|
|
WO/2013/024968A1 |
The present invention relates to a novel compound isolated from quamoclit, and to a composition containing the compound as an active ingredient, and more particularly, to a novel compound isolated from quamoclit, and to a composition for...
|
|
WO/2013/020930A1 |
The present invention relates to aminochromane, aminothiochromane and 1,2,3,4-tetrahydroquinoline derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprisin...
|
|
WO/2013/020370A1 |
Provided is a PIM kinase inhibitor as represented by formula (I), wherein E, J, Q, X, Y, Z, and m are defined in claim 1. The PIM kinase inhibitor of the present invention is used for preparing medicines for treating and preventing cance...
|
|
WO/2013/018053A1 |
The present invention relates to a novel process of synthesis of epoxides, 6-fluoro-2- (oxiran-2-yl) chroman (Figure 1), intermediates for the synthesis of nebivolol, depicted in Scheme (1), enabling to obtain the above- mentioned epoxid...
|
|
WO/2013/019662A1 |
Provided herein are glycosidic aryl naphthalide lignans compounds, such as justiprocumin A isolated from the plant Justicia gendarussa Burm.f. (Acanthaceae), which are effective in the treatment of AIDS and HIV infections.
|
|
WO/2013/016120A1 |
Compounds that include a pederin, psymberin or pederin/psymberin chimera scaffold. The pederin scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The psy...
|
|
WO/2013/012298A1 |
The present invention relates to a novel organic luminescent compound and an organic electroluminescent device containing the same. The compounds according to the present invention have high luminous efficiency and long operation lifetim...
|
|
WO/2013/012829A1 |
The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators o...
|
|
WO/2013/001352A2 |
The present invention provides a method for preparing Cleistanthin A, a diphyllin glycoside, derivatives thereof and intermediates thereto. In particular the present invention provides in one of the aspect a method for synthesis of compo...
|
|
WO/2012/176918A1 |
Specifically provided is a chromene compound represented by formula (1), which has a short fading half-life even at low temperatures in a common polymer solid matrix. (In formula (1), R1 represents a hydroxyl group or the like; each of R...
|
|
WO/2012/171175A1 |
The present invention relates to the use of Formula (I) where Y represents * denoting the point at which the moiety bonds to the bicyclic ring, in any one of its stereoisomenc forms or mixtures thereof to confer, enhance, impart and/or m...
|
|
WO/2012/173842A2 |
The present invention relates to a process for the purification of para-methallylpyrocatechol and to the preparation of flavor and fragrance compounds from para-methallylpyrocatechol.
|
|
WO/2012/170554A1 |
The invention provides molecular entities that bind with high affinity to PPARG (PPARƴ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention c...
|
|
WO/2012/162115A2 |
The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
|
|
WO/2012/161877A1 |
Compounds of the formula (I) in which R, R1 and X have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKKε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases
|
|
WO/2012/162113A1 |
The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
|
|
WO/2012/157832A1 |
The present invention relates to a photocurable isosorbide derivative, a manufacturing method thereof, and a photocurable composition including the same, more specifically to an environmentally friendly biomass-derived photocurable compo...
|
|
WO/2012/150826A1 |
An organic electroluminescent compound of formula 1 and an organic electroluminescent device comprising the same is disclosed. The organic luminescent compound provides an organic electroluminescent device which has high luminous efficie...
|
|
WO/2012/151142A2 |
Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these comp...
|
|
WO/2012/149157A2 |
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for t...
|
|
WO/2012/143340A1 |
The present invention relates to ethynyl derivatives of formula (I), wherein, Y is N or C-R3;and R3 is hydrogen, methyl, halogen or nitrile; R1 is phenyl or pyridinyl, which are optionally substituted by halogen, lower alkyl or lower alk...
|
|
WO/2012/140642A1 |
Biologically active compounds, which are useful for treating a sexual disorder, are provided herein. Further provided are pharmaceutical compositions formulated for transdermal composition, which comprise a biologically active compound u...
|
|
WO/2012/142513A1 |
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutic...
|
|
WO/2012/140596A1 |
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...
|
|
WO/2012/140243A1 |
The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.
|
|
WO/2012/138776A1 |
The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diab...
|
|
WO/2012/137181A1 |
The present invention relates to compounds of formula (1) as claimed in claim 1, their use in the treatment or the prevention of viral disorders, including HIV. (Formula I)
|
|
WO/2012/128530A2 |
The present invention relates to novel 2-methyl-2-alkyl-6-amido-2H-benzopyran derivatives having an excellent NF-ĸB target gene expression inhibitory activity and pharmaceutically acceptable salts thereof, a preparation method of the co...
|
|
WO/2012/120018A1 |
The process of the invention relates to a compound of formula (I), the process for preparing same from reduced sugar and aldehyde and the uses of these compounds in particular as surfactant.
|
|
WO/2012/110470A1 |
The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein n, Y, R1, R2, R3, and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Furthe...
|
|
WO/2012/101043A1 |
The present invention relates to pyrazole compounds of formula (1a) or (1b) and pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n and R3 have one of the meanings as indicated in the speci...
|
|
WO/2012/102357A1 |
The purpose of the present invention is to provide a compound having a potent and sustained activity of decreasing an intraocular pressure and having no adverse side effect on eyes. A compound represented by general formula (I) (wherein ...
|
|
WO/2012/098217A1 |
The present invention relates to compounds of general formula (I), wherein the groups R1, LP, LQ, X1, X2, X3, A, n and m are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR...
|
|
WO/2012/095858A1 |
The present invention is directed to a process for the preparation of l,3:2,4-bis (4- methylbenzylidene) sorbitol (MDBS) and 1,3:2,4-bis (4-dimethylbenzylidene) sorbitol (DMDBS) by dehydrocondensating an aldehyde and an alditol using a h...
|
|
WO/2012/095857A1 |
This invention is directed to a process for preparation of acetal derivatives, 1,3:2,4-bis (3,4-dimethylbenzylidene) sorbitol (DMDBS) and 1,3:2,4-bis (4-methylbenzylidene) sorbitol (MDBS) by carrying out a dehydrocondensation reaction by...
|
|
WO/2012/070015A9 |
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...
|
|
WO/2012/097270A1 |
The present application is directed to solid forms of compounds of formula (I): and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and sal...
|
